

SmartPA Criteria Proposal

Drug/Drug Class:	Ulcerative Colitis Agents, Oral PDL Edit
First Implementation Date:	June 19, 2012
Proposed Date:	March 17, 2022
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Ulcerative colitis (UC) is a chronic, inflammatory bowel disease that affects roughly one million people in the United States. There is currently no cure for this disease state, but the 2018 American Gastroenterological Association guidelines on the management of mild-to-moderate UC offer recommendations on providing symptom relief and improving quality of life through long-term remission. The treatment recommendations include the 5-aminoosalicylic class of medication which consists of balsalazide, mesalamine, olsalazine, and sulfasalazine, which are generally indicated for the treatment of active mild-to-moderate UC and/or induction or maintenance of remission. Oral budesonide is indicated only for the induction of remission in patients with active mild-to-moderate UC as there is limited efficacy or safety data for the use of budesonide for maintenance of remission.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Balsalazide Lialda® Pentasa® Sulfasalazine DR & IR 	<ul style="list-style-type: none"> Apriso® Asacol HD® Azulfidine® Azulfidine EN-tabs® Budesonide (gen Uceris®) Colazal® Delzicol® Dipentum® Mesalamine Caps/Tabs Ortikos™ Uceris®

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Ulcerative Colitis Agents, Oral
- Age Range: All appropriate MO HealthNet participants aged 2 years or older

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 3 preferred agents
 - Documented trial period of preferred agents **OR**
 - Documented ADE/ADR to preferred agents **AND**
- For Azulfidine and Azulfidine EN-tabs: participant aged 2 years or older
- For Colazal, Delzicol or Lialda: participant aged 5 years or older
- For Ortikos: participant aged 8 years or older
- For all other agents: participant aged 18 years or older

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosing limitations for the following:

APRISO ER 0.375 GM CAPSULE		4 capsules
ASACOL HD DR 800 MG TABLET		
AZULFIDINE 500 MG TABLET		
AZULFIDINE ENTAB 500 MG	SULFASALAZINE	8 tablets
COLAZAL 750 MG CAPSULE	BALSALAZIDE	9 capsules
DELZICOL DR 400 MG CAPSULE	MESALAMINE	6 capsules
DIPENTUM 250 MG CAPSULE	OLSALAZINE	2 capsules
	MESALAMINE	4 tablets
	BUDESONIDE	1 capsule
	BUDESONIDE	1 capsule
	AMINOSALICYLIC ACID	3 packets
	MESALAMINE	8 capsules
	MESALAMINE	8 capsules
	BUDESONIDE	1 tablet

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
 Rule Type: PDL

SmartPA PDL Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: “Ulcerative Colitis Agents, Oral – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; January 2022.
- Evidence-Based Medicine Analysis: “Oral Ulcerative Colitis Agents”, UMKC-DIC; November 2021.
- Ko CW, Singh S, Feuerstein JD, et al, on behalf of the American Gastroenterological Association Institute Clinical Guidelines Committee. *Gastroenterology*. 2018 Dec 18. pii: S0016-5085(18)35407-6. doi: 10.1053/j.gastro.2018.12.009. [Epub ahead of print].
- Centers for Disease Control and Prevention. (2020). Data and Statistics; Inflammatory Bowel Disease Prevalence (IBD) in the United States. Retrieved from <https://www.cdc.gov/ibd/data-statistics.htm>.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.

DRAFT